Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the
global fourth quarter net sales of OLYSIO® (simeprevir) amounted to 44 MUSD.
The royalty for the third quarter amounted to 31 MSEK (3.4 MEUR). Medivir’s
royalties based on sales for the fourth quarter are calculated from the third
|OLYSIO® global net sales |Sales in MUSD | |
|Market |Q4 -2015|Q4-2014|Change |
|US |-1 |256 |-100% |
|RoW |45 |65 |-31% |
|Total global net sales MUSD|44 |321 |-86% |
Medivir will publish its Financial Statement 2015 on February 18 2016, at 8.30
CET, followed by a conference call for investors, analysts and the media at
14.00 CET. More information about the conference call/webcast will be posted at
For more information please contact:
Ola Burmark, CFO, Medivir AB, mobile: +46 725 480 580
Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 13.30 CET on 26 January 2016.
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.